Free Trial

Teva Pharmaceutical Industries (TEVA) Competitors

$16.93
+0.03 (+0.18%)
(As of 05/31/2024 ET)

TEVA vs. TAK, ALNY, GMAB, RPRX, BGNE, BMRN, VTRS, UTHR, RDY, and SRPT

Should you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.

Teva Pharmaceutical Industries vs.

Teva Pharmaceutical Industries (NYSE:TEVA) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Takeda Pharmaceutical has a net margin of 6.18% compared to Teva Pharmaceutical Industries' net margin of -2.88%. Teva Pharmaceutical Industries' return on equity of 37.33% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries-2.88% 37.33% 6.73%
Takeda Pharmaceutical 6.18%9.92%4.71%

Teva Pharmaceutical Industries has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

In the previous week, Teva Pharmaceutical Industries had 14 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 20 mentions for Teva Pharmaceutical Industries and 6 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 0.38 beat Takeda Pharmaceutical's score of 0.29 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
4 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Takeda Pharmaceutical
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries received 1213 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 67.61% of users gave Teva Pharmaceutical Industries an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

CompanyUnderperformOutperform
Teva Pharmaceutical IndustriesOutperform Votes
1313
67.61%
Underperform Votes
629
32.39%
Takeda PharmaceuticalOutperform Votes
100
56.82%
Underperform Votes
76
43.18%

Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$15.85B1.20-$559M-$0.41-41.29
Takeda Pharmaceutical$28.20B1.50$994.06M$0.5524.27

Teva Pharmaceutical Industries presently has a consensus price target of $15.75, indicating a potential downside of 6.97%. Takeda Pharmaceutical has a consensus price target of $14.00, indicating a potential upside of 4.87%. Given Takeda Pharmaceutical's higher possible upside, analysts plainly believe Takeda Pharmaceutical is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TEVA vs. The Competition

MetricTeva Pharmaceutical IndustriesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$18.98B$6.78B$5.18B$17.81B
Dividend YieldN/A2.65%2.76%3.51%
P/E Ratio-41.2916.38121.3624.70
Price / Sales1.20276.472,394.8210.16
Price / Cash4.8132.7035.6519.14
Price / Book2.526.085.555.90
Net Income-$559M$138.60M$106.13M$976.46M
7 Day Performance1.99%3.29%1.15%0.62%
1 Month Performance20.28%0.05%0.65%3.61%
1 Year Performance134.33%-3.68%2.68%20.81%

Teva Pharmaceutical Industries Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TAK
Takeda Pharmaceutical
1.0154 of 5 stars
$13.12
flat
$14.00
+6.7%
-16.0%$41.51B$28.20B23.8549,095
ALNY
Alnylam Pharmaceuticals
4.7008 of 5 stars
$150.06
+1.6%
$216.19
+44.1%
-21.3%$18.98B$1.83B-55.992,100Insider Selling
GMAB
Genmab A/S
3.1102 of 5 stars
$28.01
+0.0%
$48.50
+73.2%
-28.3%$18.52B$2.39B23.342,204Short Interest ↑
RPRX
Royalty Pharma
4.87 of 5 stars
$26.64
+0.1%
$46.75
+75.5%
-17.4%$15.92B$2.36B19.8851Positive News
BGNE
BeiGene
2.6676 of 5 stars
$153.11
+0.3%
$251.93
+64.5%
-33.4%$14.65B$2.76B-20.2310,600Short Interest ↓
News Coverage
Positive News
BMRN
BioMarin Pharmaceutical
4.982 of 5 stars
$74.43
-1.4%
$106.11
+42.6%
-14.9%$14.13B$2.42B69.563,401Insider Selling
VTRS
Viatris
0.7831 of 5 stars
$10.39
-0.2%
$11.00
+5.9%
+15.5%$12.37B$15.43B-173.1738,000Insider Selling
UTHR
United Therapeutics
4.7711 of 5 stars
$269.15
-1.4%
$309.44
+15.0%
+28.9%$11.94B$2.50B12.731,168Insider Selling
RDY
Dr. Reddy's Laboratories
0.4872 of 5 stars
$70.94
+2.0%
$81.00
+14.2%
+23.0%$11.84B$3.35B17.6025,863Positive News
SRPT
Sarepta Therapeutics
4.7687 of 5 stars
$113.33
-8.2%
$164.47
+45.1%
+4.5%$10.71B$1.24B1,030.271,314Analyst Forecast
High Trading Volume

Related Companies and Tools

This page (NYSE:TEVA) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners